Sarepta Therapeutics (SRPT) shares fell as much as 4.8% in premarket trading Monday, poised to extend losses for a second ...

U.S. regulators asked Sarepta Therapeutics on Friday to voluntarily halt shipments of its Elevidys gene therapy after a ...

The U.S. Food and Drug Administration is planning to ask Sarepta Therapeutics to voluntarily stop all shipments of its gene ...

美国食品药品管理局（FDA）要求Sarepta Therapeutics Inc.（SRPT）暂停分销Elevidys。 要求该公司暂停Elevidys临床试验。 研究的受试对象可能会面临不合理的风险。 该公司拒绝自愿停止发货Elevidys。

Also on Friday, the Food and Drug Administration informally requested that Sarepta voluntarily pause shipments of another gene therapy, Elevidys, which is approved to treat a different type of ...

Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene ...

Investing.com - 摩根大通已将Sarepta Therapeutics (NASDAQ: SRPT )的目标价从28.00美元下调至20.00美元，同时维持对该股的"增持"评级。该股目前交易价格为14.08美元，过去一年已下跌超过90%，分析师目标价范围从9美元到110美元不等。根据 InvestingPro 分析，该股票在当前水平下显得被低估。

Investing.com - Leerink Partners将Sarepta Therapeutics (NASDAQ: SRPT )的评级从"跑赢大盘"下调至"与大盘持平"，并将目标价从45.00美元大幅下调至10.00美元。该股在过去一年已经损失了超过90%的价值，目前交易价格接近其52周低点12.81美元。根据 InvestingPro 数据，该公司市值已降至13.8亿美元。

In a highly unusual move, Cambridge-based Sarepta said late Friday won’t comply with a request from the Food and Drug ...

Sarepta (SRPT) plans to continue Elevidys shipments for Duchenne muscular dystrophy, despite FDA request not to do so after ...

Sarepta Therapeutics announced a layoff of 493 employees, including 80 in Franklin County, amid restructuring efforts and ...

Sarepta Therapeutics to lay off 493 workers, including 80 in Ohio, amid FDA probe, stock plunge, and concerns over Duchenne ...